Research Priorities for Precision Medicine in NAFLD

Paula Iruzubieta, Ramon Bataller, María Teresa Arias-Loste, Marco Arrese, José Luis Calleja, Graciela Castro-Narro, Kenneth Cusi, John F. Dillon, María Luz Martínez-Chantar, Miguel Mateo, Antonio Pérez, Mary E. Rinella, Manuel Romero-Gómez, Jörn M. Schattenberg, Shira Zelber-Sagi, Javier Crespo, Jeffrey V. Lazarus

Research output: Contribution to journalReview articlepeer-review

Abstract

NAFLD is a multisystem condition and the leading cause of chronic liver disease globally. There are no approved NAFLD-specific dugs. To advance in the prevention and treatment of NAFLD, there is a clear need to better understand the pathophysiology and genetic and environmental risk factors, identify subphenotypes, and develop personalized and precision medicine. In this review, we discuss the main NAFLD research priorities, with a particular focus on socioeconomic factors, interindividual variations, limitations of current NAFLD clinical trials, multidisciplinary models of care, and novel approaches in the management of patients with NAFLD.

Original languageEnglish
Pages (from-to)535-551
Number of pages17
JournalClinics in Liver Disease
Volume27
Issue number2
DOIs
StatePublished - May 2023

Bibliographical note

Funding Information:
J.L. Calleja reports consultancy and speaker fees from Echosens, Advanz Ph, and MSD, outside of the submitted work. K. Cusi is a consultant for Altimmune, Akero, Arrowhead, AstraZeneca, 89Bio, BMS, Coherus, Intercept, Lilly, Madrigal, Merck, Novo Nordisk, Quest, Sagimet, Sonic Incytes, Terns, Thera Technologies, and MSD, outside of the submitted work. J.F. Dillon has received research grants and lecture honoraria from MSD , AbbVie, and Gilead , outside of the submitted work. M.L. Martínez-Chantar advises for Mitotherapeutix LCC, outside of the submitted work. J.M. Schattenberg reports consultancy for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthcare GmbH and research Funding from Gilead Sciences , Boehringer Ingelheim , Nordic Bioscience , and Siemens Healthcare GmbH , outside of the submitted work. J. Crespo reports consulting and personal fees from Gilead Sciences, AbbVie, MSD, Shionogi, Intercept Pharmaceuticals, Janssen Pharmaceuticals Inc, Celgene, and Alexion, outside of the submitted work. J.V. Lazarus acknowledges grants and speaker fees from AbbVie, Gilead Sciences, and MSD and speaker fees from Genfit, Intercept, Janssen, Novo Nordisk, and ViiV, outside of the submitted work. P. Iruzubieta, R. Bataller, M.T. Arias-Loste, M. Arrese, G. Castro-Narro, M. Mateo, A. Pérez, M.E. Rinella, M. Romero-Gómez, and S. Zelber-Sagi have nothing to disclose.

Funding Information:
The authors acknowledge the Valdecilla Biomedical Research Institute (Santander, Spain) for supporting the International Precision Medicine Forum: NAFLD Updated. J.V. Lazarus acknowledges institutional support to ISGlobal from the Spanish Ministry of Science , Innovation and Universities, through the “Centro de Excelencia Severo Ochoa 2019 to 2023” Program ( CEX2018-000806-S ), and from the Government of Catalonia , Spain, through the CERCA Programme. Funding from the Spanish Instituto de Salud Carlos III Grant (FIS - PI18/01304 to J. Crespo) and from the Agencia Nacional de Investigación y Desarrollo ( ANID) , Chile (to M. Arrese) is also acknowledged.

Keywords

  • Disease phenotyping
  • Multidisciplinary care
  • NAFLD
  • Non-invasvie tests (NITs)
  • Precision medicine

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Research Priorities for Precision Medicine in NAFLD'. Together they form a unique fingerprint.

Cite this